Daniel Peterson is an American physician in private practice in the state of Nevada, and has been described as a "pioneer" in the treatment of Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
During the 1990 CFIDS Conference in Charlotte, North Carolina, Peterson described positive results in 15 CFS patents after he treated them with Ampligen for approximately 6 months.
[1] In 1990 and 1991, Peterson was one of four principal investigators for the FDA approved phase II randomized placebo controlled double-blind study of the experimental intravenous drug Ampligen.
[10] Hemispherx Biopharma's New Drug Application for marketing and sale of Ampligen to treat ME/CFS was rejected in December 2009 because the FDA concluded that the two RCTs "did not provide credible evidence of efficacy.
[13] He is a coauthor of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols, initiated by Health Canada and published by an international group of researchers in 2003.
[21] Peterson was part of the founding board and is a past-president of the International Association for CFS/ME,[3] a professional organization advocating for the interests of ME/CFS researchers and clinicians worldwide.